Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 6Radiotherapy, Intensity-Modulated 5Cisplatin 5Carboplatin 5Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4artesunic acid 3artemisinin 3Paclitaxel 3Human Papillomavirus Recombinant Vaccine nonavalent 3artenimol 2Vaccines, Synthetic 2Taxes 2Radiation 2Imiquimod 2GX-188 vaccine 2Docetaxel 2Albumin-Bound Paclitaxel 2utomilumab 1toripalimab 1polyphenon E 1infigratinib 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1aldesleukin 1Viusid 1Vaccines 1VP-102 1Therapies, Investigational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Papillomavirus Infections × Viusid × Clear all
NCT03584308 2019-05-22

Efficacy of VIUSIDĀ® Plus GLIZIGENĀ® in Patients With Papilloma Virus Esophageal

Catalysis SL

Phase 2 Completed
110 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚔